Please check your internet connection and try again.
### Sompraz%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp (Pantoprazole Sodium)
## Overview
Pantoprazole sodium is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Healing of erosive esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Doses typically range from 40 mg to 80 mg orally or intravenously every 24 hours. Doses should be titrated to reduce gastric acid secretion. Maximum recommended intravenous dose is 80 mg every 24 hours.
## Pediatric Dosing
Dosing is not established for pediatric patients.
## Dose Adjustments
No dose adjustment is required for patients with hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Less Common: Rash, pruritus, insomnia, fatigue, arthralgia.
Serious: Clostridium difficile-associated diarrhea, bone fractures (hip, wrist, spine) with long-term use, hypomagnesemia, vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs requiring gastric pH for absorption:** Ketoconazole, itraconazole, iron salts, digoxin, mycophenolate mofetil. Pantoprazole may decrease absorption.
* **CYP2C19 Substrates:** Methotrexate. Pantoprazole may increase methotrexate levels.
* **CYP2C19 Inhibitors:** Fluconazole. May increase pantoprazole levels.
* **CYP2C19 Inducers:** St. John's Wort, Rifampin. May decrease pantoprazole levels.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremor, tetany, seizures, dizziness, arrhythmias).
* Monitor for signs of bone fracture risk (consider bone density screening in patients with risk factors and long-term use).
* Monitor for symptoms of vitamin B12 deficiency with long-term use.
* Monitor for signs of C. difficile infection.
## Clinical Pearls
* Administer 30 minutes prior to a meal.
* Tablets can be crushed and mixed with applesauce or apple juice for patients with difficulty swallowing.
* Long-term use may be associated with an increased risk of C. difficile infection, bone fractures, and vitamin B12 deficiency.
* When used for maintenance of healing, consider the lowest effective dose.
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines before making any clinical decisions.
